© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women’s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses the phase III SOPHIA trial, which is exploring margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in the treatment of patients with HER2-positive breast cancer.